Role of epigenetics in Alzheimer's and Parkinson's disease.

Alzheimer's disease (AD) and Parkinson's disease (PD) are two common neurodegenerative diseases that result in the progressive damage or death of neurons. Environmental agents have the potential to damage the developing and mature nervous system, resulting in neurodegenerative diseases. Heritable changes in gene expression that do not involve coding sequence modifications are referred to as 'epigenetic'. These modifications include DNA methylation and downstream modification of histones. Environmental factors, including heavy metals and dietary folate intake, perturb neurodegenerative genes by epigenetic means, leading to altered gene expression and late-onset neurodegenerative diseases. Research into the genetic control of DNA methylation indicates an allelic skewing in a significant proportion of genes. This phenomenon may determine how an individual's genetic makeup can alter the effect an environmental factor has on their risk of developing neurodegeneration. Finally, preliminary evidence using cell culture and transgenic animal models suggests that whole classes of pan-epigenetic modifiers will have significant protective effects against common neurodegenerative diseases.

[1]  F. D’Anselmi,et al.  S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production , 2005, Molecular and Cellular Neuroscience.

[2]  G. Gores,et al.  Calpains Can Do It Alone: Implications for Cancer Therapy , 2003, Cancer biology & therapy.

[3]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[4]  N. Savaraj,et al.  Glutathione depletion-induced thymidylate insufficiency for DNA repair synthesis. , 1997, Biochemical and biophysical research communications.

[5]  G. Toffoli,et al.  Pharmacogenetic relevance of MTHFR polymorphisms. , 2008, Pharmacogenomics.

[6]  A. L. La Spada,et al.  Targeting protein aggregation in neurodegeneration – lessons from polyglutamine disorders , 2006, Expert opinion on therapeutic targets.

[7]  R. Marconi,et al.  ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease , 2007, Neurology.

[8]  Glycogen synthase kinase‐3β and tau genes interact in Parkinson's and Alzheimer's diseases , 2009, Annals of neurology.

[9]  H. Fukata,et al.  Epigenetic alteration by the chemical substances, food and environmental factors , 2004, Reproductive medicine and biology.

[10]  D. Shen,et al.  Past adult lead exposure is linked to neurodegeneration measured by brain MRI , 2006, Neurology.

[11]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[12]  Frank D. Gilliland,et al.  Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. , 2009, American journal of respiratory and critical care medicine.

[13]  Yunlong Liu,et al.  Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation , 2009, Epigenetics.

[14]  Sareen S. Gropper,et al.  Advanced Nutrition and Human Metabolism , 1990 .

[15]  F. Domann,et al.  Epigenetic Regulation of Manganese Superoxide Dismutase Expression in Human Breast Cancer Cells , 2006, Epigenetics.

[16]  M. Barrachina,et al.  DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain , 2009, Journal of neuropathology and experimental neurology.

[17]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[18]  K. Fischbeck,et al.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. , 2007, The Journal of clinical investigation.

[19]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[20]  R. Tanzi,et al.  The genetic epidemiology of neurodegenerative disease. , 2005, The Journal of clinical investigation.

[21]  Lucia Migliore,et al.  Genetic and environmental factors in cancer and neurodegenerative diseases. , 2002, Mutation research.

[22]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[23]  R. Plomin,et al.  Allelic skewing of DNA methylation is widespread across the genome. , 2010, American journal of human genetics.

[24]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[25]  Lijun Cheng,et al.  Genetic control of individual differences in gene-specific methylation in human brain. , 2010, American journal of human genetics.

[26]  Oliver Kaut,et al.  Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains , 2010, The Journal of Neuroscience.

[27]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[28]  Aldo Quattrone,et al.  Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.

[29]  Kunlin Chen,et al.  The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. , 2009, Biochemical and biophysical research communications.

[30]  T. Spector,et al.  Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Girelli,et al.  A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[33]  Paulo P. Amaral,et al.  RNA regulation of epigenetic processes , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[35]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[36]  D. Ashline,et al.  Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine , 2003, Neurobiology of Disease.

[37]  C. Van Lint,et al.  The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.

[38]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[39]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[40]  D. Cohen,et al.  Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects* , 1999, The Journal of Biological Chemistry.

[41]  E. Hirsch,et al.  Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin , 2003, Brain Research.

[42]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[43]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[44]  Joseph Rogers,et al.  Epigenetic changes in Alzheimer's disease: Decrements in DNA methylation , 2010, Neurobiology of Aging.

[45]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[46]  R. Diaz-Arrastia,et al.  Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation , 2007, The Journal of Neuroscience.

[47]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[48]  Yi Zhang,et al.  Mechanisms of epigenetic inheritance. , 2007, Current opinion in cell biology.

[49]  F. Coppedè,et al.  Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. , 2009, Mutation research.

[50]  A. Norman,et al.  A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A J Lees,et al.  Tau gene and Parkinson’s disease: a case–control study and meta-analysis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[52]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[53]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[54]  Rolf Ohlsson,et al.  Widespread Monoallelic Expression , 2007, Science.

[55]  Peter R Schofield,et al.  GSK3B polymorphisms alter transcription and splicing in Parkinson's disease , 2005, Annals of neurology.

[56]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[57]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[58]  Ramon Diaz-Arrastia,et al.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. , 2008, JAMA.

[59]  A. Roddam,et al.  Folate intake and colorectal cancer risk: A meta‐analytical approach , 2005, International journal of cancer.

[60]  F. Domann,et al.  An epigenetic perspective on the free radical theory of development. , 2007, Free radical biology & medicine.

[61]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[62]  F. D’Anselmi,et al.  B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-β deposition in mice , 2008, Molecular and Cellular Neuroscience.

[63]  N. Scott,et al.  Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study , 2007, Occupational and Environmental Medicine.

[64]  A. Fuso,et al.  B vitamin deficiency promotes tau phosphorylation through regulation of GSK3beta and PP2A. , 2010, Journal of Alzheimer's disease : JAD.

[65]  Johannes Kornhuber,et al.  DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism , 2005, Neuroreport.

[66]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[67]  R. Itzhaki,et al.  The significance of environmental factors in the etiology of Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[68]  C. Lautier,et al.  Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. , 2008, American journal of human genetics.

[69]  S. Tomar,et al.  Folate: a functional food constituent. , 2009, Journal of food science.

[70]  J. Rogers,et al.  Epigenetic Differences in Cortical Neurons from a Pair of Monozygotic Twins Discordant for Alzheimer's Disease , 2009, PloS one.

[71]  M. Endres,et al.  Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury , 2008, Experimental Neurology.

[72]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[73]  N. Zawia,et al.  The Environment, Epigenetics and Amyloidogenesis , 2009, Alzheimer's & Dementia.

[74]  N. Zawia,et al.  Epigenetics, oxidative stress, and Alzheimer disease. , 2009, Free radical biology & medicine.

[75]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[76]  Dean P. Jones,et al.  Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[77]  Sun-Chong Wang,et al.  Age-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease , 2008, PloS one.

[78]  S. Beach,et al.  The effect of smoking on MAOA promoter methylation in DNA prepared from lymphoblasts and whole blood , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[79]  T. Sanders,et al.  Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma , 2005, Gut.

[80]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[81]  A. Kanthasamy,et al.  Environmental Neurotoxic Pesticide Increases Histone Acetylation to Promote Apoptosis in Dopaminergic Neuronal Cells: Relevance to Epigenetic Mechanisms of Neurodegeneration , 2010, Molecular Pharmacology.

[82]  Jesus Avila,et al.  Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.

[83]  Demao Chen,et al.  Alzheimer's Disease (AD)-Like Pathology in Aged Monkeys after Infantile Exposure to Environmental Metal Lead (Pb): Evidence for a Developmental Origin and Environmental Link for AD , 2008, The Journal of Neuroscience.

[84]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[85]  D. Small,et al.  Presenilins and the γ-secretase: still a complex problem , 2010, Molecular Brain.

[86]  M. D'Esposito,et al.  Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia , 2003, The Lancet.

[87]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[88]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[89]  Jason H. Moore,et al.  Exploiting the proteome to improve the genome-wide genetic analysis of epistasis in common human diseases , 2008, Human Genetics.

[90]  O. Combarros,et al.  Association between Glycogen Synthase Kinase-3β Genetic Polymorphism and Late-Onset Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[91]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[92]  R. Basha,et al.  The Fetal Basis of Amyloidogenesis: Exposure to Lead and Latent Overexpression of Amyloid Precursor Protein and β-Amyloid in the Aging Brain , 2005, The Journal of Neuroscience.

[93]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[94]  Erdahl T. Teber,et al.  Tau haplotypes regulate transcription and are associated with Parkinson's disease , 2004, Annals of neurology.

[95]  M. Owen,et al.  Glycogen synthase kinase‐3β and tau genes interact in Alzheimer's disease , 2008, Annals of neurology.

[96]  D. Geschwind,et al.  HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model , 2008, PloS one.

[97]  R Alexandra Goldbohm,et al.  Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. , 2003, Cancer research.

[98]  Li-Huei Tsai,et al.  Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.

[99]  Steven Laureys,et al.  Cerebral response to patient's own name in the vegetative and minimally conscious states , 2007, Neurology.

[100]  Xiang Gao,et al.  Prospective study of dietary pattern and risk of Parkinson disease. , 2007, The American journal of clinical nutrition.

[101]  Ze Yang,et al.  Association of MTHFR gene polymorphism C677T with susceptibility to late-onset alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[102]  G. Johnson,et al.  The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. , 2006, Current Alzheimer research.

[103]  Shu G. Chen,et al.  Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease , 2009, Journal of neuroscience research.

[104]  J. Hardy,et al.  Has the amyloid cascade hypothesis for Alzheimer's disease been proved? , 2006, Current Alzheimer research.

[105]  Andrea Fuso,et al.  Changes in Presenilin 1 gene methylation pattern in diet-induced B vitamin deficiency , 2011, Neurobiology of Aging.

[106]  Amy Chan,et al.  Folate deprivation increases presenilin expression, gamma‐secretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S‐adenosyl methionine , 2007, Journal of neurochemistry.

[107]  F. Coppedè.  One-Carbon Metabolism and Alzheimer’s Disease: Focus on Epigenetics , 2010, Current genomics.